<p>Embecta（纳斯达克代码：EMBC）总裁兼首席执行官 Devdatt Kurdikar 表示，该公司最近在美国的业务重组反映了客户特定的市场份额损失、市场趋势疲软和库存相关因素的综合影响，同时强调这家糖尿病设备制造商正在继续实施更广泛的多元化战略，旨在减少对其核心胰岛素注射业务的依赖。</p>
<p>在美国银行的一次活动上，Kurdikar 将公司最近的一个季度——Embecta 的财政第二季度和日历第一季度——形容为 “无疑是一个具有挑战性的季度”。他说，美国业务大约占 Embecta 全球业务的一半，在公司分拆后，尽管经历了与 COVID 相关的干扰和通货膨胀压力，但这一业务在多年内一直保持稳定。</p>
<p>他说，这种情况在最新的季度发生了变化，因为多个因素汇聚在一起，导致财政 2026 年的指导下调。</p>
<h2>美国重组受市场份额损失、市场疲软和库存驱动</h2>
<p>Kurdikar 表示，Embecta 在一家大型美国零售商那里失去了市场份额，尽管其产品仍然可以通过该客户获得。他说，该公司在该零售商的排名从第一位降至第二位。</p>
<p>“在这种情况下，我会说最大的因素是价格，” Kurdikar 说，并补充说问题不在于产品质量，Embecta 也不认为更广泛的竞争格局发生了实质性变化。</p>
<p>他说，市场份额损失对收入的影响与销量不成比例，因为受影响的患者可能在报销多种产品的支付计划中，而这些计划的回扣低于优先或独占计划。</p>
<p>Kurdikar 还指出，胰岛素笔处方的疲软，Embecta 将其视为领先指标。他表示，胰岛素笔处方在很长一段时间内保持稳定，但最近显示出下降的迹象，尤其是在零售方面。他说，长效胰岛素的下降比速效胰岛素更为明显，新处方也可见下降。</p>
<p>其他因素包括批发商寻求更高效率的库存调整、注射器的长期下降回归，以及公司决定在全球范围内停止棉签的生产。Kurdikar 表示，棉签的利润相对较低，Embecta 未能找到合格的活性成分供应商。</p>
<h2>公司关注 GLP-1、保险变化和零售趋势</h2>
<p>Kurdikar 表示，Embecta 仍在评估最近的市场疲软是暂时的还是结构性的。他说，公司在过去几周内看到客户特定市场份额损失的稳定，但需要更多关于胰岛素笔处方趋势的数据。</p>
<p>他说，Embecta 正在考虑市场疲软的几种可能解释，包括 GLP-1 药物的可负担性提高和《平价医疗法案》补贴的到期。Kurdikar 指出，泵的采用率稳步上升，但表示他没有看到泵采用的突然加速迹象。</p>
<p>根据 Kurdikar 的说法，如果患者失去保险，他们可能会继续通过低成本选项使用胰岛素，但可能会从零售笔针转向低成本的现金支付、私人品牌或在线替代品。他表示，这可能有助于解释为什么零售笔针的下降似乎大于零售胰岛素笔的下降。</p>
<p>他还表示，GLP-1 的可负担性在去年日历年末有所改善，可能加速了 GLP-1 的使用，而新的胰岛素启动则有所减弱。Kurdikar 警告说，Embecta 只有大约三个月的数据，并表示公司在其指导中假设当前条件将持续到今年剩余时间。</p>
<h2>多元化战略仍然是核心</h2>
<p>Kurdikar 表示，公司当前的战略可以追溯到大约 18 个月前决定终止其贴片泵项目、专注于减少债务并追求多元化。他说，Embecta 开始开发新的笔针和新的注射器，以向面临价格压力的客户提供低价替代品。</p>
<p>新的注射器已在中国首次商业销售，新的笔针正在美国、巴西和欧洲的 CE 标志进行监管审查，Kurdikar 说。</p>
<p>Embecta 还在建立与仿制 GLP-1 药物相关的 B2B 渠道。Kurdikar 表示，在大约 30 家仿制药公司合作伙伴中，40% 选择了 Embecta 作为供应商。他说，印度的仿制药推出大多与 Embecta 的笔针共同包装，两家合作伙伴已在加拿大获得批准，巴西可能在今年内发生。中国可能在明年，他说。</p>
<p>Kurdikar 表示，公司之前将与 GLP-1 相关的 B2B 机会描述为至少 1 亿美元，并且在过去一年中，这一机会显得 “越来越真实”。</p>
<h2>Owen Mumford 交易预计将加速转型</h2>
<p>Kurdikar 表示，Embecta 对即将进行的 Owen Mumford 交易感到兴奋，他将其描述为扩展胰岛素注射输送到更广泛的医疗设备和药物输送平台的一种方式。</p>
<p>他说，Owen Mumford 带来了主要在欧洲和美国部分地区销售的医疗设备，而 Embecta 则拥有全球商业基础设施，特别是在拉丁美洲和亚洲。Kurdikar 表示，Embecta 计划通过自己的商业渠道将 Owen Mumford 的医疗设备组合全球化。</p>
<p>他还强调了 Owen Mumford 的药物输送能力，包括自动注射器和可重复使用的笔注射器，并表示收购的业务为制药公司开发了定制的自动注射器。该交易包括 1 亿美元的预付款和 5000 万美元的里程碑付款，后者与新产品相关。</p>
<p>Kurdikar 表示，Embecta 并未对有意义的制造成本协同效应进行建模，仅包含了一小部分运营费用协同效应。他提到，潜在的机会包括制造网络优化、后台整合、物流节省和分销效率。</p>
<h2>现金流、债务偿还和资本配置</h2>
<p>尽管指导方针进行了调整，Kurdikar 表示，Embecta 仍预计今年将产生约 1 亿美元的自由现金流。他表示，这一数字包括大约 4000 万美元的一次性成本，其中约 3000 万美元与公司的品牌转型相关。</p>
<p>他还讨论了 Embecta 最近的资本配置变化，包括将季度股息从每股 0.15 美元减少至 0.01 美元，并获得董事会批准的 1 亿美元为期三年的股票回购授权。</p>
<p>Kurdikar 表示，这一变化为 Embecta 提供了在股票回购和债务偿还之间灵活运用自由现金流的空间，他将这两项视为自由现金的主要用途。展望未来，他表示公司不会提供 2027 财年的指导，但指出可能影响未来现金流的因素，包括 Owen Mumford 的收入、GLP-1 B2B 的增长、新的笔针、新的注射器、整合成本以及与自动注射器平台相关的可能的或有支付。</p>
<p>Kurdikar 表示，困难的季度并未导致 Embecta 偏离其战略。“我们仍然相信这是正确的战略，” 他说，并补充说 Owen Mumford 的收购预计将有助于加速公司的转型。</p>
<h2>关于 Embecta NASDAQ: EMBC</h2>
<p>Embecta Corp NASDAQ: EMBC 是一家专注于糖尿病护理的纯粹公司，于 2021 年 7 月 1 日从 Becton, Dickinson and Company 分拆而出。总部位于新泽西州富兰克林湖，Embecta 专注于开发、制造和商业化能够为糖尿病患者提供胰岛素输送和血糖监测的产品。</p>
<p>该公司的产品组合包括胰岛素输注装置、耐用和贴片泵、笔针、输注管、血糖测试条、采血针和采血设备。</p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何疑问或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Embecta 吗？</h2>
<p>在考虑 Embecta 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Embecta 并不在名单上。</p>
<p>虽然 Embecta 目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>查看这五只股票</p>

EMBC

美国医药设备 ETF - iShares

标普健康医疗设备 ETF - SPDR

<p>Embecta 的首席执行官 Devdatt Kurdikar 宣布，由于市场份额下降、市场疲软和库存问题，公司将在美国进行业务重组，这将影响 2026 财年的指导。该公司正在多元化发展，超越胰岛素注射，开发新产品，并探索 GLP-1 药物的机会。Kurdikar 强调了最近与 Owen Mumford 达成的交易对扩展其医疗设备平台的重要性。尽管面临挑战，但市场份额下降的稳定迹象和对市场状况的持续评估仍在进行中</p>

<p>Embecta NASDAQ: EMBC President and CEO Devdatt Kurdikar said the company’s recent U.S. business reset reflected a combination of customer-specific share loss, softer market trends and inventory-related factors, while emphasizing that the diabetes device maker is continuing a broader diversification strategy intended to make the business less dependent on its core insulin injection franchise.</p>
<div class="lb-trans"><p>Embecta（纳斯达克代码：EMBC）总裁兼首席执行官 Devdatt Kurdikar 表示，该公司最近在美国的业务重组反映了客户特定的市场份额损失、市场趋势疲软和库存相关因素的综合影响，同时强调这家糖尿病设备制造商正在继续实施更广泛的多元化战略，旨在减少对其核心胰岛素注射业务的依赖。</p>
</div><p>Speaking at a Bank of America event, Kurdikar described the company’s most recent quarter — Embecta’s fiscal second quarter and calendar first quarter — as “unquestionably a challenging quarter.” He said the U.S. business, which represents about half of Embecta’s global business, had been stable for years following the company’s spinout, even through COVID-related disruptions and inflationary pressures.</p>
<div class="lb-trans"><p>在美国银行的一次活动上，Kurdikar 将公司最近的一个季度——Embecta 的财政第二季度和日历第一季度——形容为 “无疑是一个具有挑战性的季度”。他说，美国业务大约占 Embecta 全球业务的一半，在公司分拆后，尽管经历了与 COVID 相关的干扰和通货膨胀压力，但这一业务在多年内一直保持稳定。</p>
</div><p>That changed in the latest quarter, he said, as several factors converged and contributed to a reduction in fiscal 2026 guidance.</p>
<div class="lb-trans"><p>他说，这种情况在最新的季度发生了变化，因为多个因素汇聚在一起，导致财政 2026 年的指导下调。</p>
</div><h2>U.S. Reset Driven by Share Loss, Market Softness and Inventory</h2>
<div class="lb-trans"><h2>美国重组受市场份额损失、市场疲软和库存驱动</h2>
</div><p>Kurdikar said Embecta lost share with one large U.S. retailer, though its products remain available through that customer. He said the company moved from the No. 1 position to the No. 2 position at that retailer.</p>
<div class="lb-trans"><p>Kurdikar 表示，Embecta 在一家大型美国零售商那里失去了市场份额，尽管其产品仍然可以通过该客户获得。他说，该公司在该零售商的排名从第一位降至第二位。</p>
</div><p>“In this particular case, I would say the single largest factor was price,” Kurdikar said, adding that the issue was not product quality and that Embecta does not believe the broader competitive landscape has changed materially.</p>
<div class="lb-trans"><p>“在这种情况下，我会说最大的因素是价格，” Kurdikar 说，并补充说问题不在于产品质量，Embecta 也不认为更广泛的竞争格局发生了实质性变化。</p>
</div><p>He said the revenue impact from the share loss was disproportionate to volume because the affected patients were likely on payer plans that reimburse a range of products, where rebates are lower than on preferred or exclusive plans.</p>
<div class="lb-trans"><p>他说，市场份额损失对收入的影响与销量不成比例，因为受影响的患者可能在报销多种产品的支付计划中，而这些计划的回扣低于优先或独占计划。</p>
</div><p>Kurdikar also pointed to softness in insulin pen prescriptions, which Embecta tracks as a leading indicator. He said insulin pen prescriptions had been stable for a long period but recently showed signs of decline, particularly in retail. The decline was more pronounced in long-acting insulin than fast-acting insulin and was also visible in new prescriptions, he said.</p>
<div class="lb-trans"><p>Kurdikar 还指出，胰岛素笔处方的疲软，Embecta 将其视为领先指标。他表示，胰岛素笔处方在很长一段时间内保持稳定，但最近显示出下降的迹象，尤其是在零售方面。他说，长效胰岛素的下降比速效胰岛素更为明显，新处方也可见下降。</p>
</div><p>Other factors included inventory adjustments as wholesalers seek greater efficiency, a return to the long-term decline in syringes and the company’s decision to discontinue swabs globally. Kurdikar said swabs were a comparatively low-margin product and Embecta was unable to find a qualified supplier for an active ingredient.</p>
<div class="lb-trans"><p>其他因素包括批发商寻求更高效率的库存调整、注射器的长期下降回归，以及公司决定在全球范围内停止棉签的生产。Kurdikar 表示，棉签的利润相对较低，Embecta 未能找到合格的活性成分供应商。</p>
</div><h2>Company Watching GLP-1s, Insurance Changes and Retail Trends</h2>
<div class="lb-trans"><h2>公司关注 GLP-1、保险变化和零售趋势</h2>
</div><p>Kurdikar said Embecta is still assessing whether the recent market softness is temporary or structural. He said the company has seen stabilization in the customer-specific share loss over the past several weeks, but needs more data on insulin pen prescription trends.</p>
<div class="lb-trans"><p>Kurdikar 表示，Embecta 仍在评估最近的市场疲软是暂时的还是结构性的。他说，公司在过去几周内看到客户特定市场份额损失的稳定，但需要更多关于胰岛素笔处方趋势的数据。</p>
</div><p>He said Embecta is considering several possible explanations for market softness, including increased affordability of GLP-1 drugs and the expiration of ACA subsidies. Kurdikar noted that pump adoption has been rising steadily, but said he has not seen signs of a sudden acceleration in pump adoption.</p>
<div class="lb-trans"><p>他说，Embecta 正在考虑市场疲软的几种可能解释，包括 GLP-1 药物的可负担性提高和《平价医疗法案》补贴的到期。Kurdikar 指出，泵的采用率稳步上升，但表示他没有看到泵采用的突然加速迹象。</p>
</div><p>According to Kurdikar, if patients lose insurance, they may continue taking insulin through lower-cost options but may switch away from retail pen needles to lower-cost cash-pay, private-label or online alternatives. He said that could help explain why retail pen needle declines appear greater than retail insulin pen declines.</p>
<div class="lb-trans"><p>根据 Kurdikar 的说法，如果患者失去保险，他们可能会继续通过低成本选项使用胰岛素，但可能会从零售笔针转向低成本的现金支付、私人品牌或在线替代品。他表示，这可能有助于解释为什么零售笔针的下降似乎大于零售胰岛素笔的下降。</p>
</div><p>He also said GLP-1 affordability improved late last calendar year, potentially accelerating GLP-1 uptake while new insulin starts have softened. Kurdikar cautioned that Embecta has only about three months of data and said the company assumed in its guidance that current conditions persist through the rest of the year.</p>
<div class="lb-trans"><p>他还表示，GLP-1 的可负担性在去年日历年末有所改善，可能加速了 GLP-1 的使用，而新的胰岛素启动则有所减弱。Kurdikar 警告说，Embecta 只有大约三个月的数据，并表示公司在其指导中假设当前条件将持续到今年剩余时间。</p>
</div><h2>Diversification Strategy Remains Central</h2>
<div class="lb-trans"><h2>多元化战略仍然是核心</h2>
</div><p>Kurdikar said the company’s current strategy dates back to its decision about 18 months ago to terminate its patch pump program, focus on debt reduction and pursue diversification. He said Embecta began developing a new pen needle and a new syringe to offer lower-priced alternatives to customers facing pricing pressure.</p>
<div class="lb-trans"><p>Kurdikar 表示，公司当前的战略可以追溯到大约 18 个月前决定终止其贴片泵项目、专注于减少债务并追求多元化。他说，Embecta 开始开发新的笔针和新的注射器，以向面临价格压力的客户提供低价替代品。</p>
</div><p>The new syringe has had its first commercial sale in China, and the new pen needle is under regulatory review in the U.S., Brazil and for CE mark in Europe, Kurdikar said.</p>
<div class="lb-trans"><p>新的注射器已在中国首次商业销售，新的笔针正在美国、巴西和欧洲的 CE 标志进行监管审查，Kurdikar 说。</p>
</div><p>Embecta is also building a business-to-business channel tied to generic GLP-1 drugs. Kurdikar said that of roughly 30 generic drug company partners Embecta is speaking with, 40% have chosen Embecta as a supplier. He said generic launches in India are largely co-packaged with Embecta pen needles, two partners have received approvals in Canada and Brazil could still occur this year. China is likely next year, he said.</p>
<div class="lb-trans"><p>Embecta 还在建立与仿制 GLP-1 药物相关的 B2B 渠道。Kurdikar 表示，在大约 30 家仿制药公司合作伙伴中，40% 选择了 Embecta 作为供应商。他说，印度的仿制药推出大多与 Embecta 的笔针共同包装，两家合作伙伴已在加拿大获得批准，巴西可能在今年内发生。中国可能在明年，他说。</p>
</div><p>Kurdikar said the company previously described the GLP-1-related B2B opportunity as at least $100 million and that, over the past year, the opportunity has appeared “more and more real.”</p>
<div class="lb-trans"><p>Kurdikar 表示，公司之前将与 GLP-1 相关的 B2B 机会描述为至少 1 亿美元，并且在过去一年中，这一机会显得 “越来越真实”。</p>
</div><h2>Owen Mumford Deal Expected to Accelerate Transformation</h2>
<div class="lb-trans"><h2>Owen Mumford 交易预计将加速转型</h2>
</div><p>Kurdikar said Embecta is excited about its pending Owen Mumford transaction, which he described as a way to expand beyond insulin injection delivery into a broader medical device and drug delivery platform.</p>
<div class="lb-trans"><p>Kurdikar 表示，Embecta 对即将进行的 Owen Mumford 交易感到兴奋，他将其描述为扩展胰岛素注射输送到更广泛的医疗设备和药物输送平台的一种方式。</p>
</div><p>He said Owen Mumford brings medical devices sold primarily in parts of Europe and the U.S., while Embecta has global commercial infrastructure, particularly in Latin America and Asia. Kurdikar said Embecta plans to globalize Owen Mumford’s medical device portfolio through its own commercial channels.</p>
<div class="lb-trans"><p>他说，Owen Mumford 带来了主要在欧洲和美国部分地区销售的医疗设备，而 Embecta 则拥有全球商业基础设施，特别是在拉丁美洲和亚洲。Kurdikar 表示，Embecta 计划通过自己的商业渠道将 Owen Mumford 的医疗设备组合全球化。</p>
</div><p>He also highlighted Owen Mumford’s drug delivery capabilities, including autoinjectors and reusable pen injectors, and said the acquired business has developed bespoke autoinjectors for pharmaceutical companies. The transaction includes $100 million upfront and $50 million contingent on milestones tied to a new product, he said.</p>
<div class="lb-trans"><p>他还强调了 Owen Mumford 的药物输送能力，包括自动注射器和可重复使用的笔注射器，并表示收购的业务为制药公司开发了定制的自动注射器。该交易包括 1 亿美元的预付款和 5000 万美元的里程碑付款，后者与新产品相关。</p>
</div><p>Kurdikar said Embecta did not model meaningful manufacturing cost synergies and only included a modest amount of operating expense synergies. Potential opportunities include manufacturing network optimization, back-office rationalization, logistics savings and distribution efficiencies, he said.</p>
<div class="lb-trans"><p>Kurdikar 表示，Embecta 并未对有意义的制造成本协同效应进行建模，仅包含了一小部分运营费用协同效应。他提到，潜在的机会包括制造网络优化、后台整合、物流节省和分销效率。</p>
</div><h2>Cash Flow, Debt Paydown and Capital Allocation</h2>
<div class="lb-trans"><h2>现金流、债务偿还和资本配置</h2>
</div><p>Despite the guidance reset, Kurdikar said Embecta still expects about $100 million in free cash flow this year. He said that figure includes roughly $40 million in one-time costs, including about $30 million tied to the company’s brand transition.</p>
<div class="lb-trans"><p>尽管指导方针进行了调整，Kurdikar 表示，Embecta 仍预计今年将产生约 1 亿美元的自由现金流。他表示，这一数字包括大约 4000 万美元的一次性成本，其中约 3000 万美元与公司的品牌转型相关。</p>
</div><p>He also discussed Embecta’s recent capital allocation changes, including reducing its quarterly dividend from $0.15 per share to $0.01 per share and obtaining a $100 million, three-year share repurchase authorization from the board.</p>
<div class="lb-trans"><p>他还讨论了 Embecta 最近的资本配置变化，包括将季度股息从每股 0.15 美元减少至 0.01 美元，并获得董事会批准的 1 亿美元为期三年的股票回购授权。</p>
</div><p>Kurdikar said the change gives Embecta flexibility to deploy free cash flow between share repurchases and debt repayment, which he described as the two primary uses of free cash. Looking ahead, he said the company is not providing fiscal 2027 guidance but pointed to factors that could affect future cash flow, including Owen Mumford revenue, GLP-1 B2B growth, new pen needles, new syringes, integration costs and possible contingent payments tied to the autoinjector platform.</p>
<div class="lb-trans"><p>Kurdikar 表示，这一变化为 Embecta 提供了在股票回购和债务偿还之间灵活运用自由现金流的空间，他将这两项视为自由现金的主要用途。展望未来，他表示公司不会提供 2027 财年的指导，但指出可能影响未来现金流的因素，包括 Owen Mumford 的收入、GLP-1 B2B 的增长、新的笔针、新的注射器、整合成本以及与自动注射器平台相关的可能的或有支付。</p>
</div><p>Kurdikar said the difficult quarter is not causing Embecta to deviate from its strategy. “We still believe that’s the right strategy,” he said, adding that the Owen Mumford acquisition is expected to help accelerate the company’s transformation.</p>
<div class="lb-trans"><p>Kurdikar 表示，困难的季度并未导致 Embecta 偏离其战略。“我们仍然相信这是正确的战略，” 他说，并补充说 Owen Mumford 的收购预计将有助于加速公司的转型。</p>
</div><h2>About Embecta NASDAQ: EMBC</h2>
<div class="lb-trans"><h2>关于 Embecta NASDAQ: EMBC</h2>
</div><p>Embecta Corp NASDAQ: EMBC is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.</p>
<div class="lb-trans"><p>Embecta Corp NASDAQ: EMBC 是一家专注于糖尿病护理的纯粹公司，于 2021 年 7 月 1 日从 Becton, Dickinson and Company 分拆而出。总部位于新泽西州富兰克林湖，Embecta 专注于开发、制造和商业化能够为糖尿病患者提供胰岛素输送和血糖监测的产品。</p>
</div><p>The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.</p>
<div class="lb-trans"><p>该公司的产品组合包括胰岛素输注装置、耐用和贴片泵、笔针、输注管、血糖测试条、采血针和采血设备。</p>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何疑问或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Embecta Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Embecta 吗？</h2>
</div><p>Before you consider Embecta, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Embecta 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Embecta wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Embecta 并不在名单上。</p>
</div><p>While Embecta currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Embecta 目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Embecta Faces U.S. Reset as CEO Bets on GLP-1, Owen Mumford Diversification

Market Beat

Embecta

美国银行

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Embecta 面临美国市场重组，CEO 押注 GLP-1，Owen Mumford 寻求多元化发展